Search results
Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'
Investor's Business Daily· 10 months agoShares of REGN stock jumped Monday after the Food and Drug Administration approved Regeneron...
Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back?
Investor's Business Daily· 8 months agoRegeneron Pharmaceuticals is the IBD Stock of the Day as the biotech giant trades near an all-time...
Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers
Investor's Business Daily· 8 months agoRegeneron Pharmaceuticals' high-dose Eylea is off to a strong start in the U.S., the company said...
Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme
Investor's Business Daily· 1 year agoConfusion over new Medicare negotiating plans sent Regeneron Pharmaceuticals and Halozyme...
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
Zacks via Yahoo Finance· 2 years agoRegeneron (REGN) closed at $735.96 in the latest trading session, marking a -0.01% move from the...
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?
Zacks via Yahoo Finance· 7 months agoShares of Regeneron REGN have gained 10.3% year to date against the industry’s decline of 14.8%....
Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance Being Led By Its...
Simply Wall St. via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 22% over the past three...
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's On An Uptrend: Are Strong Financials Guiding...
Simply Wall St. via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 29% over the past three...
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock Has Fared Decently: Is the Market Following...
Simply Wall St. via Yahoo Finance· 8 months agoMost readers would already know that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased by...
The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line
Investor's Business Daily· 11 months agoRegeneron Pharmaceuticals predicted a faster-than-expected approval timeline for a high dose of its...